Alcohol and cannabis consumption in patients with inflammatory bowel disease: prevalence, pattern of consumption and impact on the disease

Gespeichert in:
Bibliographische Detailangaben
Titel: Alcohol and cannabis consumption in patients with inflammatory bowel disease: prevalence, pattern of consumption and impact on the disease
Autoren: Martinho-Grueber, Maude, Schoepfer, Alain, Maillard, Michel H, Michetti, Pierre, Brunner, Felix, Clair, Carole, Pathe Barry, Mamadou, Pittet, Valérie, von Känel, Roland, Juillerat, Pascal, Kapoglou, Ioannis, Bravo, Francisco, Sarraj, Riad, Benz, Eileen, Restellini, Sophie, Biedermann, Luc, Rogler, Gerhard, Vavricka, Stephan R
Weitere Verfasser: University of Zurich, Martinho-Grueber, Maude
Quelle: Eur J Gastroenterol Hepatol
European journal of gastroenterology & hepatology, vol. 35, no. 1, pp. 21-30
Martinho-Grueber, Maude; Kapoglou, Ioannis; Bravo, Francisco; Sarraj, Riad; Benz, Eileen; Restellini, Sophie; Biedermann, Luc; Rogler, Gerhard; Vavricka, Stephan R; Schoepfer, Alain; Maillard, Michel H; Michetti, Pierre; Brunner, Felix; Clair, Carole; Pathe Barry, Mamadou; Pittet, Valérie; von Känel, Roland; Juillerat, Pascal (2023). Alcohol and cannabis consumption in patients with inflammatory bowel disease: prevalence, pattern of consumption and impact on the disease. European journal of gastroenterology & hepatology, 35(1), pp. 21-30. Wolters Kluwer 10.1097/MEG.0000000000002453 <http://dx.doi.org/10.1097/MEG.0000000000002453>
Serveur académique lausannois
Zurich Open Repository and Archive
ORCID
Bern Open Repository and Information System (BORIS)
Datacite
Verlagsinformationen: Ovid Technologies (Wolters Kluwer Health), 2022.
Publikationsjahr: 2022
Schlagwörter: Male, 0301 basic medicine, 0303 health sciences, Hepatology, Alcohol Drinking, Ethanol, Gastroenterology, Original Articles: Gastroenterology, 610 Medicine & health, 2700 General Medicine, Inflammatory Bowel Diseases, 3. Good health, Cohort Studies, Humans, Cannabis, Prevalence, Alcohol Drinking/adverse effects, Alcohol Drinking/epidemiology, Inflammatory Bowel Diseases/epidemiology, Chronic Disease, 03 medical and health sciences, 10219 Clinic for Gastroenterology and Hepatology, 10057 Klinik für Konsiliarpsychiatrie und Psychosomatik, 610 Medizin und Gesundheit
Beschreibung: Objectives of the study There is little guidance regarding the impact of alcohol and cannabis on the clinical course of inflammatory bowel disease. The aim of this study was to assess the prevalence, sociodemographic characteristics and impact of alcohol and cannabis use on the clinical course of the disease. Methods We performed an analysis of prospectively collected data within the Swiss Inflammatory Bowel Disease Cohort Study with yearly follow-ups and substance-specific questionnaires. We analyzed the prevalence of use, the profile of users at risk for addiction and the impact of alcohol and cannabis on the course of the disease. Results We collected data of 2828 patients included between 2006 and 2018 and analyzed it according to their completion of specific surveys on alcohol and cannabis use. The prevalence of patient-reported active use was 41.3% for alcohol and 6% for cannabis. Heavy drinkers were over-represented among retired, married smokers receiving mostly aminosalicylates and less immunosuppression. In ulcerative colitis patients, low-to-moderate drinking was associated with less extensive disease. Cannabis users were often students with ileal Crohn’s disease. Conclusion A significant proportion of patients with inflammatory bowel disease consume alcohol or cannabis. Heavy alcohol consumption is most likely in male smokers >50 years, whereas young men with ileal disease rather use cannabis.
Publikationsart: Article
Other literature type
Dateibeschreibung: application/pdf; Alcohol_and_cannabis_consumption_in_patients_with.3.pdf - application/pdf
Sprache: English
ISSN: 0954-691X
DOI: 10.1097/meg.0000000000002453
DOI: 10.5167/uzh-225234
DOI: 10.48350/174413
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/36317770
https://serval.unil.ch/notice/serval:BIB_1B0BE72B83BD
https://serval.unil.ch/resource/serval:BIB_1B0BE72B83BD.P001/REF.pdf
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_1B0BE72B83BD2
https://boris.unibe.ch/174413/
https://www.zora.uzh.ch/id/eprint/225234/
https://doi.org/10.5167/uzh-225234
Rights: CC BY NC ND
Dokumentencode: edsair.doi.dedup.....6ec0cf5d98b3fd58c8973b5d0a83f25d
Datenbank: OpenAIRE
Beschreibung
Abstract:Objectives of the study There is little guidance regarding the impact of alcohol and cannabis on the clinical course of inflammatory bowel disease. The aim of this study was to assess the prevalence, sociodemographic characteristics and impact of alcohol and cannabis use on the clinical course of the disease. Methods We performed an analysis of prospectively collected data within the Swiss Inflammatory Bowel Disease Cohort Study with yearly follow-ups and substance-specific questionnaires. We analyzed the prevalence of use, the profile of users at risk for addiction and the impact of alcohol and cannabis on the course of the disease. Results We collected data of 2828 patients included between 2006 and 2018 and analyzed it according to their completion of specific surveys on alcohol and cannabis use. The prevalence of patient-reported active use was 41.3% for alcohol and 6% for cannabis. Heavy drinkers were over-represented among retired, married smokers receiving mostly aminosalicylates and less immunosuppression. In ulcerative colitis patients, low-to-moderate drinking was associated with less extensive disease. Cannabis users were often students with ileal Crohn’s disease. Conclusion A significant proportion of patients with inflammatory bowel disease consume alcohol or cannabis. Heavy alcohol consumption is most likely in male smokers >50 years, whereas young men with ileal disease rather use cannabis.
ISSN:0954691X
DOI:10.1097/meg.0000000000002453